Johnson & Johnson files for FDA approval of oral IL-23 inhibitor in psoriasis New data suggests icotrokinra could challenge injectables with once-daily targeted peptide.

https://www.drugdiscoverynews.com/j-j-files-for-fda-approval-of-oral-il-23-inhibitor-in-psoriasis-16554